Envisia Therapeuticsformed By Liquidia Technologies In 2013Is A Privately Held Biotechnology Company Focused On The Development Of Novel Ocular Therapies Envisia Is Leveraging The Unique And Powerful Properties Of The Printaplatform To Develop Therapies For A Variety Of Ocular Conditionsthe Most Advanced Of Which Is Env515For The Treatment Of Glaucoma Env515 Is A Novel Extended Release Formulation Of A Prostaglandin Analogue Formulation It Has The Potential To Significantly Limit Disease Progression And Vision Loss Through Improved Product Performance And Patient Compliance Envisia Is Located In Research Triangle Parknorth Carolina
